Telomir Pharmaceuticals disclosed that its lead small‑molecule candidate, Telomir‑1, lowered prostate‑specific antigen (PSA) levels in androgen‑responsive LNCaP prostate cancer cells in a new preclinical study. The reduction was dose‑dependent, indicating that higher concentrations of Telomir‑1 produced greater PSA suppression.
PSA is an FDA‑recognized biomarker used by clinicians to gauge treatment response in prostate cancer. The finding suggests that Telomir‑1’s metal‑ion regulatory mechanism can dampen tumor activity in a clinically relevant readout, strengthening the case for advancing the compound toward an Investigational New Drug (IND) filing.
The announcement comes as Telomir reports a Q3 2025 net loss of $1.1 million, a sharp improvement from the $5.99 million loss in the same quarter a year earlier, and a nine‑month loss of $8.35 million versus $13.63 million year‑to‑date. The company’s cash reserves are projected to fund operations through the third quarter of 2026, but management has flagged substantial doubt about its ability to continue as a going concern.
CEO Erez Aminov said the data “demonstrate the breadth of Telomir‑1’s potential, not only as a prostate cancer therapy but as a platform that could address aging‑related and rare diseases.” Chief Scientific Advisor Dr. Itzchak Angel added that the PSA reduction “provides a measurable biomarker that clinicians rely on, giving the preclinical data additional clinical relevance.”
While the study is still at the laboratory stage and does not translate into a marketed therapy, the PSA result is a significant step toward validating Telomir‑1’s efficacy and may attract investor interest and potential partnership opportunities as the company prepares for clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.